The use of non-TNF targeted biologics in Behçet's Disease: Real-life data from the International AIDA Network Behçet's Disease Registry - PubMed
4 days ago
- #Biologics
- #Refractory Treatment
- #Behçet's Disease
- Study evaluates non-TNF targeted biologics in Behçet's Disease (BD) using real-life data from the International AIDA Network Registry.
- 65 patients (mean age 45.8 years) with refractory BD were included, assessing efficacy and safety of alternative biologics.
- Anakinra was most frequently used, showing partial/complete response in mucocutaneous (34.7%), musculoskeletal (73.3%), and ocular (77.7%) involvement.
- Canakinumab demonstrated efficacy in mucocutaneous, musculoskeletal, and ocular cases, including some unresponsive to anakinra.
- Tocilizumab showed favorable outcomes in ocular and neurological involvement but limited efficacy in mucocutaneous manifestations.
- Secukinumab and ixekizumab were effective for mucocutaneous-articular phenotypes, especially with axial spondyloarthritis.
- Ustekinumab and rituximab also improved selected refractory cases, with no major safety concerns reported.
- Conclusion: IL-1, IL-6, IL-17, and IL-12/23 pathway biologics offer alternatives for TNF-α inhibitor-unresponsive BD, with efficacy varying by phenotype.